Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP

British Journal of Haematology

Volumn 135, Issue 1, 2006, Pages 33-42

  Harjunpää, Antti ^a   Taskinen, Minna ^b,c   Nykter, Matti ^d   Karjalainen Lindsberg, Marja Liisa ^a   Nyman, Heidi ^b,c   Monni, Outi ^e   Hemmer, Samuli ^b   Yli Harja, Olli ^d   Hautaniemi, Sampsa ^e,f   Meri, Seppo ^a   Leppä, Sirpa ^b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Follicular lymphoma; Microarray; Rituximab and CHOP; Treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPHRIN RECEPTOR A1; PREDNISONE; PROTEIN TYROSINE KINASE; RITUXIMAB; SCAVENGER RECEPTOR; SMAD1 PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DNA MICROARRAY; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LONG TERM CARE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MORPHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; PREDNISONE; RECEPTOR, EPHA1; SMAD PROTEINS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 33748425461     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06255.x     Document Type: Article

References (33)

1. Aasheim, H.C., Delabie, J. & Finne, E.F. (2005) Ephrin-A1 binding to CD4+ T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2. Blood, 105, 2869-2876.
2. Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson, Jr, J., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. & Staudt, L.M. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-511.
3. Berglund, M., Thunberg, U., Amini, R.M., Book, M., Roos, G., Erlanson, M., Linderoth, J., Dictor, M., Jerkeman, M., Cavallin-Stahl, E., Sundstrom, C., Rehn-Eriksson, S., Backlin, C., Hagberg, H., Rosenquist, R. & Enblad, G. (2005) Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Modern Pathology, 18, 1113-1120.
4. Bjorck, E., Ek, S., Landgren, O., Jerkeman, M., Ehinger, M., Bjorkholm, M., Borrebaeck, C.A., Porwit-MacDonald, A. & Nordenskjold, M. (2005) High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood, 105, 2908-2915.
5. Bohen, S.P., Troyanskaya, O.G., Alter, O., Warnke, R., Botstein, D., Brown, P.O. & Levy, R. (2003) Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proceedings of the National Academy of Sciences of the United States of America, 100, 1926-1930.
6. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754-758.
7. Cartron, G., Watier, H., Golay, J. & Solal-Celigny, P. (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood, 104, 2635-2642.
8. Dave, S.S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R.D., Chan, W.C., Fisher, R.I., Braziel, R.M., Rimsza, L.M., Grogan, T.M., Miller, T.P., LeBlanc, M., Greiner, T.C., Weisenburger, D.D., Lynch, J.C., Vose, J., Armitage, J.O., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Connors, J.M., Lansdorp, P.M., Ouyang, Q., Lister, T.A., Davies, A.J., Norton, A.J., Muller-Hermelink, H.K., Ott, G., Campo, E., Montserrat, E., Wilson, W.H., Jaffe, E.S., Simon, R., Yang, L., Powell, J., Zhao, H., Goldschmidt, N., Chiorazzi, M. & Staudt, L.M. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. New England Journal of Medicine, 351, 2159-2169.
9. Elomaa, O., Kangas, M., Sahlberg, C., Tuukkanen, J., Sormunen, R., Liakka, A., Thesleff, I., Kraal, G. & Tryggvason, K. (1995) Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages. Cell, 80, 603-609.
10. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A., Metzner, B., Pott, C., Hartmann, F., Rothmann, F., Rohrberg, R., Bock, H.P., Wandt, H., Unterhalt, M. & Hiddemann, W. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 104, 3064-3071.
11. Glas, A.M., Kersten, M.J., Delahaye, L.J., Witteveen, A.T., Kibbelaar, R.E., Velds, A., Wessels, L.F., Joosten, P., Kerkhoven, R.M., Bernards, R., van Krieken, J.H., Kluin, P.M., van't Veer, L.J. & de Jong, D. (2005) Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 105, 301-307.
12. Golub, T.R., Slonim, D.K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J.P., Coller, H., Loh, M.L., Downing, J.R., Caligiuri, M.A., Bloomfield, C.D. & Lander, E.S. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286, 531-537.
13. Grolleau, A., Misek, D.E., Kuick, R., Hanash, S. & Mule, J.J. (2003) Inducible expression of macrophage receptor Marco by dendritic cells following phagocytic uptake of dead cells uncovered by oligonucleotide arrays. Journal of Immunology, 171, 2879-2888.
14. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
15. Harjunpaa, A., Junnikkala, S. & Meri, S. (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scandinavian Journal of Immunology, 51, 634-641.
16. Hernandez-Ilizaliturri, F.J., Jupudy, V., Ostberg, J., Oflazoglu, E., Huberman, A., Repasky, E. & Czuczman, M.S. (2003) Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clinical Cancer Research, 9, 5810-5812.
17. Hernandez-Ilizaliturri, F.J., Jupudy, V., Reising, S., Repasky, E.A. & Czuczman, M.S. (2005) Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leukemia and Lymphoma, 46, 1775-1784.
18. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725-3732.
19. Husson, H., Carideo, E.G., Neuberg, D., Schultze, J., Munoz, O., Marks, P.W., Donovan, J.W., Chillemi, A.C., O'Connell, P. & Freedman, A.S. (2002) Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood, 99, 282-289.
20. Ishisaki, A., Yamato, K., Hashimoto, S., Nakao, A., Tamaki, K., Nonaka, K., ten Dijke, P., Sugino, H. & Nishihara, T. (1999) Differential inhibition of Smad6 and Smad7 on bone morphogenetic proteinand activin-mediated growth arrest and apoptosis in B cells. Journal of Biological Chemistry, 274, 13637-13642.
21. Jaffe, E.S., Harris, N.L. & Stein, H. (2001) Pathology and Genetics of Tumours of the Hematopoietic and Lymphoid Tissue. IARC Press, Lyon, France.
22. van der Laan, L.J., Dopp, E.A., Haworth, R., Pikkarainen, T., Kangas, M., Elomaa, O., Dijkstra, C.D., Gordon, S., Tryggvason, K. & Kraal, G. (1999) Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. Journal of Immunology, 162, 939-947.
23. Lossos, I.S., Czerwinski, D.K., Alizadeh, A.A., Wechser, M.A., Tibshirani, R., Botstein, D. & Levy, R. (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. New England Journal of Medicine, 350, 1828-1837.
24. Maloney, D.G., Smith, B. & Rose, A. (2002) Rituximab: mechanism of action and resistance. Seminars in Oncology, 29, 2-9.
25. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A. & Smith, P. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, 1417-1423.
26. Munoz, O., Fend, F., de Beaumont, R., Husson, H., Astier, A. & Freedman, A.S. (2004) TGFbeta-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation. Leukemia, 18, 2015-2025.
27. Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., Lopez-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T. & Staudt, L.M. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 1937-1947.
28. Sharfe, N., Freywald, A., Toro, A., Dadi, H. & Roifman, C. (2002) Ephrin stimulation modulates T cell chemotaxis. European Journal of Immunology, 32, 3745-3755.
29. Sharfe, N., Freywald, A., Toro, A. & Roifman, C.M. (2003) Ephrin-A1 induces c-Cbl phosphorylation and EphA receptor down-regulation in T cells. Journal of Immunology, 170, 6024-6032.
30. Shipp, M.A., Ross, K.N., Tamayo, P., Weng, A.P., Kutok, J.L., Aguiar, R.C., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G.S., Ray, T.S., Koval, M.A., Last, K.W., Norton, A., Lister, T.A., Mesirov, J., Neuberg, D.S., Lander, E.S., Aster, J.C. & Golub, T.R. (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Medicine, 8, 68-74.
31. Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J.O., Arranz-Saez, R., Au, W.Y., Bellei, M., Brice, P., Caballero, D., Coiffier, B., Conde-Garcia, E., Doyen, C., Federico, M., Fisher, R.I., Garcia-Conde, J.F., Guglielmi, C., Hagenbeek, A., Haioun, C., LeBlanc, M., Lister, A.T., Lopez-Guillermo, A., McLaughlin, P., Milpied, N., Morel, P., Mounier, N., Proctor, S.J., Rohatiner, A., Smith, P., Soubeyran, P., Tilly, H., Vitolo, U., Zinzani, P.L., Zucca, E. & Montserrat, E. (2004) Follicular lymphoma international prognostic index. Blood, 104, 1258-1265.
32. The International Non-Hodgkin's Lymphoma Prognostic Factor Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 329, 987-994.
33. Yamato, K., Hashimoto, S., Imamura, T., Uchida, H., Okahashi, N., Koseki, T., Ishisaki, A., Kizaki, M., Miyazono, K., Ikeda, Y. & Nishihara, T. (2001) Activation of the p21(CIP1/WAF1) promoter by bone morphogenetic protein-2 in mouse B lineage cells. Oncogene, 20, 4383-4392.